These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20422704)

  • 1. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
    Hadley JA; Mösges R; Desrosiers M; Haverstock D; van Veenhuyzen D; Herman-Gnjidic Z
    Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis.
    Ferguson BJ; Guzzetta RV; Spector SL; Hadley JA
    Otolaryngol Head Neck Surg; 2004 Sep; 131(3):207-14. PubMed ID: 15365537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
    Klossek JM; Siegert R; Nikolaidis P; Arvis P; Leberre MA;
    J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
    Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
    Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute bacterial maxillary sinusitis: time to symptom resolution and return to normal activities with moxifloxacin.
    Johnson P; Adelglass J; Rankin B; Sterling R; Keating K; Benson A; Pertel P
    Int J Clin Pract; 2008 Sep; 62(9):1366-72. PubMed ID: 18671753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxifloxacin in the treatment of acute bacterial rhinosinusitis: results of a multicenter, non-interventional study.
    Zhou B; Jiang X; Zhai L; Xiao S; Wang J; Xiao G; Ruan B; Liang C; Ye Q; Hu B; Wang H
    Acta Otolaryngol; 2010 Sep; 130(9):1058-64. PubMed ID: 20235900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
    Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset of symptom resolution in adults with acute bacterial rhinosinusitis treated with a single dose of azithromycin extended release compared with 10 days of levofloxacin: a retrospective analysis of a randomized, double-blind, double-dummy trial.
    Marple BF; Roberts CS; de Caprariis PJ; Reisman A
    Clin Ther; 2007 Dec; 29(12):2690-8. PubMed ID: 18201585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I; Gogos CA; Bassaris H
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
    Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial.
    Lizogub VG; Riley DS; Heger M
    Explore (NY); 2007; 3(6):573-84. PubMed ID: 18005909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis.
    Arrieta JR; Galgano AS; Sakano E; Fonseca X; Amábile-Cuevas CF; Hernández-Oliva G; Vivar R; González G; Torres A;
    Am J Otolaryngol; 2007; 28(2):78-82. PubMed ID: 17362810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.
    Constantinou M; Daniell M; Snibson GR; Vu HT; Taylor HR
    Ophthalmology; 2007 Sep; 114(9):1622-9. PubMed ID: 17822972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
    Ross JD; Cronjé HS; Paszkowski T; Rakoczi I; Vildaite D; Kureishi A; Alefelder M; Arvis P; Reimnitz P;
    Sex Transm Infect; 2006 Dec; 82(6):446-51. PubMed ID: 16723364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefdinir versus levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiology: a multicenter, randomized, double-blind study.
    Henry DC; Kapral D; Busman TA; Paris MM
    Clin Ther; 2004 Dec; 26(12):2026-33. PubMed ID: 15823766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial.
    Vehreschild JJ; Moritz G; Vehreschild MJ; Arenz D; Mahne M; Bredenfeld H; Chemnitz J; Klein F; Cremer B; Böll B; Kaul I; Wassmer G; Hallek M; Scheid C; Cornely OA
    Int J Antimicrob Agents; 2012 Feb; 39(2):130-4. PubMed ID: 22169408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.